NASDAQ
20.08.26 | 21:59
4,020 US-Dollar
-4,51 % -0,190
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | C4 Therapeutics GAAP EPS of -$0.18 beats by $0.05, revenue of $6.64M beats by $2.64M | 1 | Seeking Alpha | ||
| 11.08. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.08. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 24.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | C4 Therapeutics presents cemsidomide data at EHA congress | 2 | Investing.com | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.06. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory ... | 2 | GlobeNewswire (USA) | ||
| 11.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.05. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.05. | C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M | 1 | Seeking Alpha | ||
| 12.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 538 | GlobeNewswire (Europe) | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| 12.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Roche places a $1bn bet on C4T degrader-antibody conjugates | 9 | pharmaphorum | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 7 | Pharmaceutical Technology | ||
| 10.04. | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 29 | transkript.de | ||
| 09.04. | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 14 | Benzinga.com | ||
| 09.04. | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| 09.04. | C4 Therapeutics Enters Collaboration Agreement With Roche | 639 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 09.04. | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,196 | -5,38 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,106 | -0,36 % | INOVIO shares jump 18% after Q2 beat | ||
| CLINUVEL | 6,474 | +7,58 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,600 | -6,47 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,582 | -4,35 % | Cardiol Therapeutics GAAP EPS of -C$0.05 | ||
| CELLDEX THERAPEUTICS | 34,490 | -3,39 % | Celldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis | Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | -3,82 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,763 | -0,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CYTODYN | 0,170 | +1,19 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,192 | 0,00 % | Wettbewerbsdruck bei Naloxon: S&P stuft Ausblick für Emergent BioSolutions auf negativ herab | ||
| DENALI THERAPEUTICS | 21,320 | -3,09 % | DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? | ||
| CEL-SCI | 1,290 | +2,38 % | CEL-SCI Signs Saudi Arabia Multikine Commercialization Deal With 50/50 Net Revenue Split | ||
| COHERUS ONCOLOGY | 1,188 | +5,51 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,948 | -3,44 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| CURIS | 1,622 | +11,37 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,51 % bei einem Aktienkurs von 4,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.